Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis

Current Medical Research and Opinion

Volumn 31, Issue 9, 2015, Pages 1687-1691

  Derfuss, T ^a   Bergvall, N K ^b   Sfikas, N ^b   Tomic, D L ^b  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Fingolimod; High disease activity; Highly active RRMS; Multiple sclerosis

Indexed keywords

BETA INTERFERON; FINGOLIMOD; GADOLINIUM; GLATIRAMER; NATALIZUMAB; PLACEBO; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BRAIN SIZE; CLINICAL TRIAL (TOPIC); CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; EUROPEAN MEDICINES AGENCY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RECURRENCE RISK; RISK REDUCTION; TREATMENT OUTCOME; DRUG MONITORING; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATHOPHYSIOLOGY; PATIENT ACUITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION;

ADULT; DISEASE PROGRESSION; DRUG MONITORING; FEMALE; FINGOLIMOD HYDROCHLORIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT ACUITY; SECONDARY PREVENTION; TREATMENT OUTCOME;

EID: 84939817991     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1067191     Document Type: Article

References (14)

1. Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A doubleblind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 545-56
2. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387-401
3. Cohen JA, Barkhof F, Comi G, et al. Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. J Neurol 2013; 260: 2023-32
4. Devonshire V, Havrdova E, Radue EW, et al. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of the double blind, randomised, placebo-controlled FREEDOMS study. Lancet Neurol 2012; 11: 420-8
5. Goodin D, Jeffery D, Kappos L, et al. Fingolimod reduces annualized relapse rate in patients with relapsing-remitting multiple sclerosis: FREEDOMS II study subgroup analysis. Poster presented at the 65th American Academy of Neurology Annual Meeting, 16-23 March 2013, San Diego, USA: PO7.102
6. European Medicines Agency. European Public Assessment Report for Gilenya, annex I, summary of product characteristics. 2011; Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002202/WC500104528.pdf [Last accessed March 2015]
7. Healy BC, Engler D, Glanz B, et al. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int 2013; 2013: 189624
8. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt Sinai J Med 2011; 78: 161-75
9. Portaccio E, Zipoli V, Siracusa G, et al. Long-Term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 2008; 59: 131-5
10. Castillo-Trivino T, Mowry EM, Gajofatto A, et al. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One 2011; 6: E16664
11. Carrithers MD. Update on disease-modifying treatments for multiple sclerosis. Clin Ther 2014; 36: 1938-45
12. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402-15
13. Khatri B, Barkhof F, Comi G, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: A randomised extension of the TRANSFORMS study. Lancet Neurol 2011; 10: 520-9
14. He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol 2015; 72: 405-13